Monthly SOM230C for Recurrent or Progressive Meningioma

Inclusion Criteria: * 18 years of age or older * Radiographically measurable disease on contrast-enhanced MRI or CT images * Karnofsky Performance status of 60 or greater * Life expectancy of at least 3 months * Histologically confirmed diagnosis of recurrent or progressive intracranial meningioma(s). This includes benign, atypical, or malignant meningioma; patients with neurofibromatosis type 1 or 2 may participate. Participants without histological confirmation but a classic radiographic picture of meningioma may also enroll. Patients with neurofibromatosis type 2 and a classic radiographic picture of meningioma may also enroll without histological confirmation * At least ten unstained standard (4-5 micron) paraffin slides for immunohistochemistry. Participants who have not had a surgical procedure are exempt from this requirement * Unequivocal evidence for tumor progression by MRI (or CT scan if MRI is contraindicated) * MRI or CT must be performed within 14 days of registration * Patients with malignant meningiomas who require corticosteroids must be on a stable dose for at least 5 days prior to baseline imaging. * For patients who have been treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval of 4 or more weeks must have elapses from the completion of radiation therapy to study drug administration, and there must be evidence of tumor progression. * There is no limit on the number of prior therapies Exclusion Criteria: * Any cytotoxic chemotherapy, radiation, immunotherapy, or experimental therapy within 4 weeks prior to study drug administration * Prior therapy with somatostatin, andy somatostatin analogue, or any other hormonal treatment prescribed for the purpose of treating meningioma * Major surgery within 4 weeks prior to study drug administration * Malabsorption syndrome, short bowel or chologenic diarrhea not controlled by specific therapeutic means * Poorly controlled diabetes mellitus * Symptomatic cholelithiasis * Congestive heart failure, unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment * QTc \> 450 msec * Risk factors for Torsades de Pointes such as hypokalemia (\< 3.5 mmol/L) not corrected by treatment, hypomagnesemia (\< 0.7 mmol/L or \< 1.6 mg/dL) not corrected by treatment, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block * Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure * Concomitant medication(s) known to increase the QT interval within 4 weeks prior to study drug administration * Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis with serum bilirubin \> 2x ULN, serum albumin \< 0.67 LLN, or ALT or AST more than 2 x ULN * Any other primary malignancy within the past 3 years (with the exception of basal cell carcinoma or carcinoma in situ of the cervix) * Active or suspected acute or chronic, uncontrolled infection or any history of immunocompromise, including any positive HIV test result * Abnormal coagulation studies (PT or PTT elevated by 30% above normal limits) * Use of anticoagulant medications (not including anti-platelet medications) * Lab values as specified in the protocol * Any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator * Pregnancy or lactation, or failure to practice a medically acceptable method of birth control * History of alcohol or drug abuse in the 6 month period before study enrollment * Participation in any clinical investigation with an investigational drug within 1 month prior to study drug administration * Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide LAR os s.c. formulations